May 15, 2019

Novartis today announced the results from the global Phase III trial evaluating the investigational PI3K inhibitor were published in The New England Journal of Medicine. The trial evaluated the efficacy and safety of the investigational PI3K inhibitor in postmenopausal women, and men, with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer with a PIK3CA mutation that progressed on or after an aromatase inhibitor with or without a CDK4/6 inhibitor.


The publication is available online here.

See also the media release SOLAR-1 trial.